Vascular stent maker Vesper Medical reels in $10.5M in series A round

Money
Vesper Medical, a developer of devices for minimally invasive peripheral vascular procedures, raised $10.5 million in series A financing. (jansucko/iStock/Getty Images Plus/Getty Images)

Vesper Medical, which focuses on developing devices for minimally invasive peripheral vascular procedures, raised $10.5 million in a series A round of financing.

The funds will be used by the Wayne, Pennsylvania-based company to complete the development of its Vesper Duo Venous Stent System and the in vivo testing needed to move to clinical testing of the device, the company said.

Participating in the financing, which was completed in two tranches, were New Enterprise Associates and Quaker Partners.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Deep venous disease effects millions of people globally. Typical treatment includes using elastic compression stockings and blood thinners, but those don’t address the blockage or narrowing of veins.

“There are more than 25 million U.S. adults suffering the debilitating consequences of deep venous disease, and traditional treatments fall short for many of them,” Bruce Shook, president and CEO of Vesper, said in a statement. “We see an enormous opportunity to deliver a lasting solution for these patients that is tailor made to the unique requirements of the deep veins.”

Clotting or narrowing of the veins of the pelvis or upper leg can create blockages that reduce blood flow that can lead to symptoms such as severe leg swelling, pain, skin discoloration and even ulcers.

Read more on

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.